IDDF2019-ABS-0077 Percutaneous Endobiliary Radiofrequency Ablation and Self-Expandable Metal Stent Placement Versus Stent Placement Alone for Malignant Biliary Obstruction
Wei Cui,Jiaping Li
DOI: https://doi.org/10.1136/gutjnl-2019-iddfabstracts.255
IF: 24.5
2019-01-01
Gut
Abstract:Background To retrospectively evaluate the added benefit of adding endobiliary radiofrequency ablation (EB-RFA) to biliary metal stent placement for patients with malignant biliary obstruction (MBO). Methods From November 2013 to June 2018, 163 patients with MBO who had undergone percutaneous EB-RFA and stent placement (RFA-stent group, n = 90) or stent placement only (Stent group, n = 73) were included. According to the causes of biliary obstruction, the two treatment groups were divided into Cholangiocarcinoma Subgroup, Pancreatic carcinoma Subgroup and Remaining disease Subgroup. Overall survival(OS), primary and secondary stent patency (PSP, SSP), complications between the two groups were compared, and the prognostic factors of OS, PSP and SSP were analyzed. Results RFA-Stent group resulted in better median OS (7.0 vs 4.5 months, P= 0.034), PSP (8.0 vs 5.1 months, P=0.003) and SSP (9.8 vs 5.1 months, P < 0.001) than Stent group (figure 1). In Cholangiocarcinoma subgroup, the median OS in two groups was 8.0 months and 4.7 months, respectively, P = 0.791; The median PSP and SSP in RFA-Stent group were longer than that Stent group( PSP: 8.0 months vs 6.0 months, P = 0.024, respectively; SSP: 9.0 months vs 6.0 months, respectively, P < 0.001) (figure 2). In Pancreatic carcinoma subgroup, RFA-Stent group resulted in better median OS (8.5 vs 4.0 months, P= 0.006), PSP (8.5 vs 4.5 months, P=0.021) and SSP (9.8 vs 4.5 months, P = 0.004) than Stent group(figure 3). There was no statistical difference in OS, PSP and SSP between the two groups in Remaining subgroup(figure 4). The complications were comparable between the two groups. Multivariate analysis showed that treatment methods, performance status score, postoperative combination therapy, obstruction etiology, obstruction location type, preoperative bilirubin level and postoperative bilirubin decreased value were independent prognostic factors for survival. Treatment methods, previous treatment for primary disease and preoperative bilirubin level were independent prognostic factors for PSP and SSP. Conclusions RFA-Stent confers therapeutic benefits in patients with unresectable MBO, especially in those patients with pancreatic carcinoma.